by 
Acute bacterial skin and skin structure infections (ABSSSI) refer to bacterial infections of the skin with a lesion size area of ≥75 cm2, including cellulitis/erysipelas, wound or surgical site infections and major cutaneous abscesses with surrounding erythema, edema, or induration. Common causative pathogens include Staphylococcus aureus and Streptococcus pyogenes. These infections are commonly associated with underlying skin disorders, trauma to the skin, surgery or invasive procedures. With rising incidence of skin disorders such as atopic dermatitis, psoriasis, and traumatic injuries owing to accidents or lifestyle changes, the instances of ABSSSI have witnessed a significant increase over the past few years.
The global acute bacterial skin and skin structure infections market is estimated to be valued at US$ 3,466.6 in 2023 and is expected to exhibit a CAGR of 6.0% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Dynamics:
One of the major drivers fueling the acute bacterial skin and skin structure infections market growth is the increasing incidence of skin infections. The skin, being the largest organ of the body, is highly prone to various bacterial, fungal and viral infections. Changing lifestyle patterns, rising pollution levels and increasing prevalence of lifestyle diseases like diabetes are contributing significantly to the rising instances of skin infections globally. According to the American Academy of Dermatology, about 75% of all urgent care visits in the US are skin related, with skin infections accounting for a major proportion. Moreover, growing resistance to antibiotic drugs due to their inappropriate and extended use has led to treatment difficulties, thereby propelling the demand for advanced drugs with novel mechanisms of action to treat ABSSSI. The aforementioned factors are expected to support the market growth over the forecast period.
Segment Analysis
The global acute bacterial skin and skin structure infections market is dominated by the hospital pharmacy sub-segment. The hospital pharmacy sub-segment holds around 60% market share owing to the preference of patients to receive treatment and medication for such infections from hospitals. Increased reliance on hospitals for effective diagnosis and treatment of infections is supporting the growth of this sub-segment.
PEST Analysis
Political: Governments across various countries are introducing supportive policies and regulations to reduce antimicrobial resistance and enhance availability of effective treatment options for bacterial infections. This is positively impacting the market growth.
Economic: Rising healthcare spending coupled with growing incidence of skin infections due to changing lifestyles is driving the demand. The market is expected to witness higher growth in developing nations experiencing economic growth.
Social: Increasing awareness about various skin disorders and availability of treatment is encouraging people to seek proper diagnosis and medication. Growing adoption of unhealthy habits like smoking is leading to higher prevalence of infections.
Technological: Continuous research and development activities by players for development of novel drug formulations with improved efficacy is boosting the market. Introduction of combination therapies is also augmenting the market expansion.
Key Takeaways
The global acute bacterial skin and skin structure infections market is expected to witness high growth. The rising prevalence of skin infections due to factors such as growing incidence of chronic diseases, increasing healthcare expenditure, and changing climatic conditions are fueling the demand for effective treatments.
Regional analysis: North America holds a significant share in the market owing to growing incidence of obesity and associated risk of infections. Favorable reimbursement policies are further supporting market growth. Asia Pacific is anticipated to showcase fastest growth over the forecast period with expanding patient pool, developing healthcare infrastructure, and increasing chronic disease burden in regional economies like India and China.
Key players operating in the acute bacterial skin and skin structure infections market are Fresenius SE & Co. KGaA, Pfizer, Inc., Amneal Pharmaceuticals LLC, Intas Pharmaceuticals Ltd., Cadila Healthcare Ltd., Glenmark Pharmaceuticals Ltd, GlaxoSmithKline plc., Sun Pharmaceutical Industries Ltd., Sandoz Inc., Aurobindo Pharma Ltd., AbbVie, Inc., Melinta Therapeutics, Inc., Accord Healthcare Ltd., Merck & Co., Inc., Teva Pharmaceutical Industries Ltd., and Paratek Pharmaceuticals, Inc. Key players are focusing on new product launches and enhancing their presence in emerging markets through collaborations.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
